Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.2500 (-8.7%) ($4.8200 - $5.5900) on Wed. Dec. 12, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.81% (three month average) | RSI | 50 | Latest Price | $5.2500(-8.7%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -2.4% a day on average for past five trading days. | Weekly Trend | ADAP advances 2% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) SMH(19%) GDXJ(12%) UNG(12%) FXI(11%) JETS(11%) | Factors Impacting ADAP price | ADAP will decline at least -2.905% in a week (0% probabilities). XLP(-11%) XLV(-9%) VIXM(-9%) IFRA(-7%) VXX(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.905% (StdDev 5.81%) | Hourly BBV | 0 () | Intraday Trend | -5.4% | | | |
|
Resistance Level | $5.66 | 5 Day Moving Average | $5.67(-7.41%) | 10 Day Moving Average | $5.78(-9.17%) | 20 Day Moving Average | $5.66(-7.24%) | To recent high | -62.9% | To recent low | 2.7% | Market Cap | $812m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |